AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24445955
Drug: Extended caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended caffeine treatment
Trial: 22585223
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin and 900 mg rifapentine twice weekly
Trial: 22585223
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin and 1,200 mg rifapentine once weekly
Trial: 17355800
Drug: Remifentanyl infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanyl infusion at 0.1 microg x kg(‐1) x min(‐1)
Trial: 17355800
Drug: Fentanyl bolus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl bolus injection at 1.5 microg x kg(‐1)
Trial: 17355800
Drug: Remifentanyl infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanyl infusion
Trial: 17355800
Drug: Fentanyl bolus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl bolus injection
Trial: 15833578
Drug: mecamylamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mecamylamine (10 mg)
Trial: 1683411
Drug: tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tertatolol 5 mg o.d.
Trial: 31420397
Drug: Usual prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual prophylaxis strategy up to month +6 followed by pre-emptive therapy up to month +12
Trial: 30066184
Drug: Thermoplastic aligners
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoplastic aligners (clear transparent PET-G thermoplastic sheets)
Trial: 26963896
Drug: Rapid intravenous
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intravenous rehydration (3 litres Hartman's solution over 6 hours) and ongoing midwifery telephone support
Trial: 23298702
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (30-minute musical session with headset)
Trial: 21466589
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment (0.1%)
Trial: 17074021
Drug: rebamipide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rebamipide (100 mg, t.i.d.)
Trial: 14561278
Drug: Oral creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral creatine supplementation (5 g d(‐1) for six weeks)
Trial: 27472572
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Dexamethasone and Ondansetron
Trial: 27472572
Drug: Dexamethasone, Ondansetron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, Ondansetron, Combination
Trial: 20932179
Drug: Daily salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily salt intake measurement
Trial: 18325757
Drug: Testosterone-in-adhesive matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone-in-adhesive matrix patch (4.8 mg testosterone daily, 2 patches of 60 cm2 every 48 hours)
Trial: 18325757
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone enanthate injection (every 3 weeks)
Trial: 11216754
Drug: Lexipafant 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lexipafant 10 mg
Trial: 11216754
Drug: Lexipafant 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lexipafant 100 mg
Trial: 9010144
Drug: Six months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six months of oral anticoagulant therapy
Trial: 9010144
Drug: Indefinite oral
RxNorm normalized name: TITANIUM DIOXIDE 3.25 mL in 35 mL CUTANEOUS CREAM [PHYTOGENIC INFINITE FOUNDATION SPF20 NB21]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indefinite oral anticoagulant therapy
Trial: 3321865
Drug: Vasopressin antagonist
RxNorm normalized name: Vasopressin antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin antagonist (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin) 10 micrograms/kg body weight
Trial: 30397714
Drug: Knowledge assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge assessment of dental hygienists regarding systemic diseases and oral health
Trial: 26955679
Drug: Jiakangling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiakangling Capsule (JC) combined with reduction of 131I (50-80 microCi per gram of thyroid tissue) taken for one month after 131I treatment.
Trial: 26955679
Drug: Jiakangling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiakangling Capsule (JC) combined with reduction of 131I.
Trial: 18201433
Drug: Control (Inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Inhaled Fluticasone Propionate)
Trial: 22045080
Drug: Adenosine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (both doses)
Trial: 9470002
Drug: L-Thyroxine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Thyroxine (8 micrograms/kg birthweight per day)
Trial: 29445858
Drug: L-Thyroxine
RxNorm normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Thyroxine
Trial: 2505682
Drug: 5-FU +
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU + PSK (3 g/day for 4 weeks and 5-FU 150 mg/day for 4 weeks, 10 courses)
Trial: 26357419
Drug: 1.5 L
RxNorm normalized name: NUTREN 1.5 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 L daily of EVIAN water on top of usual intake for 50 days
Trial: 25033919
Drug: Acupuncture (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (twice a week for 4 weeks)
Trial: 21256670
Drug: Placebo (sham-acupuncture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham-acupuncture, twice a week for 4 weeks)
Trial: 17761230
Drug: DASH diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH diet (rich in fruits, vegetables, and low-fat dairy products) at intermediate sodium level (2,300 mg/day)
Trial: 17761230
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet at intermediate sodium level (2,300 mg/day)
Trial: 15669554
Drug: Estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (2 mg) and trimegestone (TMG 0.25 or 0.5 mg)
Trial: 8294170
Drug: Ketoprofen 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 2.5% gel applied twice a day for seven days (250 mg per day)
Trial: 8294170
Drug: Ketoprofen 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 2.5% gel
Trial: 3327724
Drug: Aminophylline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (1.5 mg/kg)
Trial: 29402711
Drug: Tamsulosin alone:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin alone: 0.2 mg/d
Trial: 29402711
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg/d plus celecoxib: 200 mg/d
Trial: 27281374
Drug: Drug Attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug Attention Control Training Program (Drug‐ACTP)
Trial: 25428341
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride dispersible tablet (Control)
Trial: 23713299
Drug: Chemotherapy (Navelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Navelbine and cisplatin)
Trial: 16600816
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) supplementation at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Trial: 10867111
Drug: R121919 (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R121919 (5-40 mg)
Trial: 10867111
Drug: R121919 (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R121919 (40-80 mg)
Trial: 1297878
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical trainings without coronary active agents
Trial: 1297878
Drug: Physical exercises
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercises with antianginal drugs (first control group)
Trial: 1297878
Drug: Therapeutical exercises,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutical exercises, graded walking, nitrates, beta-blockers, calcium antagonists (second control group)
Trial: 6381170
Drug: Theocontin Continus
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theocontin Continus tablets
Trial: 28646416
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (solifenacin 5 mg plus mirabegron 25 mg for the first 4 weeks/50 mg for the last 8 weeks)
Trial: 2288826
Drug: Sulpiride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (400 mg)
Trial: 15084619
Drug: High-dose sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sequential chemotherapy and autografting
Trial: 12404273
Drug: No estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No estrogen replacement therapy (No ERT)
Trial: 350590
Drug: β‐acetyl digoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐acetyl digoxin (D) 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg daily for 7 days
Trial: 350590
Drug: digitoxin (Dt)
RxNorm normalized name: Digitoxin
DrugBank: Digitoxin (DB01396)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digitoxin (Dt) 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days
Trial: 30592476
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (2 μg/kg)
Trial: 23497981
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal water)
Trial: 30676487
Drug: Single 900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 900mg oral dose of delafloxacin
Trial: 30676487
Drug: Single 250mg
RxNorm normalized name: docusate
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 250mg intramuscular ceftriaxone
Trial: 25172875
Drug: Computerized insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computerized insulin infusion program (CIIP)
Trial: 22775976
Drug: AZD1656 (7,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (7, 20, 40 or 80 mg) twice daily for 8 days
Trial: 22775976
Drug: AZD1656 (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (15-45 mg) twice daily for 28 days
Trial: 8506191
Drug: nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nisoldipine 10 mg twice a day for 8 weeks
Trial: 8506191
Drug: nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 20 mg twice a day for 8 weeks
Trial: 2965139
Drug: Oral procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral procaterol hydrochloride at 25 micrograms
Trial: 27145977
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone (2 to 8 mg) delivered in low volumes (0.1 to 0.2 mL) using an Aptar Unit‐Dose device
Trial: 27145977
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone (4 mg) delivered in a single device (0.1 mL)
Trial: 24675370
Drug: IA injection
RxNorm normalized name: factor VIIa Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA injection of 30IU of BoNT A
Trial: 22617279
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg per day of lactotripeptides for 3 months
Trial: 22617279
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per day of lactotripeptides for 3 months
Trial: 9722212
Drug: University of
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: University of Wisconsin solution (UW group)
Trial: 9722212
Drug: Bretschneider's Histidine‐Tryptophan‐Ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretschneider's Histidine‐Tryptophan‐Ketoglutarate solution (HTK group)
Trial: 8067218
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural bupivacaine/morphine for 48 h postoperatively plus oral piroxicam
Trial: 8067218
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia followed by a conventional intramuscular opioid and acetaminophen regimen
Trial: 31362882
Drug: Intravenous Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ketamine 0.5mg.kg‐1 (Group K‐IV)
Trial: 31362882
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and Nebulized Ketamine Groups
Trial: 28062595
Drug: 68Ga-PSMA-11 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-PSMA-11 PET/CT at 3 h after injection
Trial: 28062595
Drug: 68Ga-PSMA-11 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-PSMA-11 PET/CT at 1 h after injection
Trial: 28062595
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg) before late scans
Trial: 28062595
Drug: Late scans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late scans (3 h after injection)
Trial: 28062595
Drug: Early scans
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early scans (1 h after injection)
Trial: 23896980
Drug: Sirukumab 1
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 1 mg/kg
Trial: 23896980
Drug: Sirukumab 4
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 4 mg/kg
Trial: 23896980
Drug: Sirukumab 10
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 10 mg/kg
Trial: 28052588
Drug: Sirukumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab (all doses)
Trial: 22321594
Drug: Vaccine group
RxNorm normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine group (n=81)
Trial: 22321594
Drug: Vaccine group
RxNorm normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine group (n=25)
Trial: 18927241
Drug: Vernakalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vernakalant hydrochloride injection (3 mg/kg initially via 10-minute intravenous infusion followed by a second 2 mg/kg 10-minute infusion if atrial fibrillation persisted)
Trial: 18927241
Drug: Vernakalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vernakalant hydrochloride injection (1 or 2 infusions)
Trial: 18927241
Drug: Vernakalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vernakalant hydrochloride injection
Trial: 11206684
Drug: Sildenafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (5 to 200 mg)
Trial: 9795316
Drug: ACLS medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACLS medications (epinephrine, atropine, bicarbonate, calcium, lidocaine)
Trial: 30759221
Drug: Subcutaneous denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous denosumab 60 mg every 6 months for 3 years, then 7 years of open-label denosumab
Trial: 30759221
Drug: Subcutaneous denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous denosumab 60 mg
Trial: 28392436
Drug: PRX-106 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX-106 (all doses)
Trial: 23263473
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (5.25 mg/kg)
Trial: 21109557
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 25 mg subcutaneous injections twice weekly
Trial: 10492661
Drug: Itraconazole pulse
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole pulse therapy (1 week 400 mg daily, 3 months)
Trial: 10492661
Drug: Continuous terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous terbinafine dosing (250 mg daily, 3 months)
Trial: 1725023
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 or 10 mg daily)
Trial: 30908754
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Tranexamic Acid
Trial: 21968126
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg daily
Trial: 10326743
Drug: Pidotimod (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod (400 mg oral bottle/day for 90 days)
Trial: 7927099
Drug: Flupirtine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (100 mg, n = 35)
Trial: 7927099
Drug: Tramadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50 mg, n = 36)
Trial: 83088
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin solution
Trial: 131310
Drug: 0.025% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% tretinoin solution
Trial: 25459098
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal ring (CVR) - 15 mcg ethinyl estradiol/150 mcg etonogestrel
Trial: 25459098
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (COC) - 20 mcg ethinyl estradiol/100 mcg levonorgestrel
Trial: 17324745
Drug: bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol (5 mg)
Trial: 16492206
Drug: Pioglitazone 30-45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30-45 mg/day
Trial: 16492206
Drug: Gliclazide 80-320
RxNorm normalized name: gliclazide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 80-320 mg/day
Trial: 8355859
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg tid
Trial: 8355859
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg tid
Trial: 23053685
Drug: Scapular-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scapular-focused treatment
Trial: 22166673
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with daily interruption
Trial: 19092340
Drug: TAC-ST (Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-ST (Tacrolimus - Short-term Steroid)
Trial: 12900683
Drug: L-arginine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine + CHO (10 g L-arginine with 70 g carbohydrate)
Trial: 9109106
Drug: m-CPP administration
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP administration
Trial: 29490012
Drug: Structured, moderate-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured, moderate-intensity physical activity (PA) program consisting of center-based (twice/week) and home-based (three to four times per week) aerobic, resistance, and flexibility training
Trial: 26858193
Drug: Everolimus initiated
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus initiated at 4.5 mg/m2/day, titrated to blood trough levels of 5-15 ng/mL.
Trial: 24453831
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (DD) of aspirin and clopidogrel (n = 58)
Trial: 24453831
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) of aspirin and clopidogrel (n = 58)
Trial: 24453831
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (DD) of aspirin and clopidogrel
Trial: 18256968
Drug: Psychotherapy methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy methods (brief interventions and cognitive-behavioral therapy)